You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 11, November 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, LONDON, APRIL 27 TO APRIL 30, 1987-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Inflammatory Breast Carcinoma

Effective Multimodal Approach

Gary V. Burton, MD; Edwin B. Cox, MD; George S. Leight, Jr, MD; Leonard R. Prosnitz, MD; James D. Iglehart, MD; Gregg A. Olsen, MD; Hilliard F. Seigler, MD; Lowell L. Hart, MD

Arch Surg. 1987;122(11):1329-1332.


Abstract

• Twenty-two patients with inflammatory breast carcinoma received preoperative chemotherapy consisting of weekly administration of cyclophosphamide, doxorubicin hydrochloride, fluorouracil, and vincristine sulfate for six weeks. Postoperative therapy consisted of 22 weeks of biweekly administration of these drugs. Regional radiotherapeutic consolidation followed chemotherapy. Nineteen patients completed therapy. Twelve of these patients remain disease free (median, 15 months; range, four to 32 months). Median disease-free survival for all 22 patients is 13 months or more (range, zero to 32 months). Median overall survival is 18 months or more (range, one to 33 months). This regimen compares favorably with prolonged adjuvant and maintenance chemotherapy for inflammatory breast carcinoma.

(Arch Surg 1987;122:1329-1332)



Author Affiliations

From the Departments of Medicine (Drs Burton, Cox, Olsen, and Hart), Surgery (Drs Leight, Iglehart, and Seigler), and Radiation Therapy (Dr Prosnitz), Duke University Medical Center, Durham, NC. Dr Burton is now with the Department of Medicine, Louisiana State University Medical Center, Shreveport.


Footnotes

Accepted for publication July 13, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 26, 1987.

Reprint requests to Department of Medicine, Hematology/Oncology Section, Louisiana State University Medical Center, 1501 Kings Highway, Shreveport, LA 71130 (Dr Burton).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inflammatory Breast Cancer
Moore et al.
Arch Surg 1991;126:304-306.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.